

# Clinical Oversight Meets Patient Convenience: In-Home Phototherapy Done Right

## The Problem

Phototherapy is a safe, effective and clinically proven treatment for certain chronic skin conditions. But until now, home phototherapy has been challenging to access.

Prior authorization hurdles, complex billing and prescription processes, frequent insurance denials and limited visibility into adherence - especially for at-home care, add to an already high administrative burden and delays in treatment.

Delays in care caused 68% of patients to experience worsened flares and 35% reported mental health impacts, <sup>1</sup> lowering their overall satisfaction with treatments, and providers.

## Introducing: The Zerigo Skin Health Platform

- **FDA-Cleared, Handheld Device\***: Narrowband ultraviolet light (UVB) used for at-home or on-the-go treatment, backed by clinical research.
- **Intelligent Software**: Remotely monitor, and engage patients and easily access treatment data - in real-time - to help provide interventions where and how patients need them.
- **1:1 Patient Engagement**: Licensed professionals support treatment and refer patients back to providers as-needed to extend your care beyond the clinic.
- **Dedicated Provider Support**: Reclaim your office hours with a dedicated team of staff to take on the administrative burdens of documentation, reporting, eligibility and prescription processing.

## Why Providers Partner With Zerigo



### Safe, Proven, Effective

80% of members achieved clear/almost clear skin at 12 weeks<sup>2</sup>, with a 4.9/5 patient satisfaction rating<sup>3</sup>



### High Adherence Rates

Real time patient communication & monitoring leads to 75% adherence<sup>4</sup>



### Time to Treatment

<5 days from enrollment to starting treatment



### Seamless Integration

No prior authorization needed. Zerigo works with your current systems

## Key Success Metrics\*\*, Psoriasis

Metric	Zerigo	TNF-α Inhibitors	Interleukin Inhibitors	PDE Inhibitors
Adherence	75%	50-63% <sup>5</sup>	46-72% <sup>5</sup>	62% <sup>6</sup>
Clear/PASI-75 16 weeks <sup>7</sup>	74-90%	40-80%	62-89%	30.8%
Common Adverse Events <sup>8</sup>	Erythema <1%	53-58%	46-49%	41%
Retention (12-month) / Persistence <sup>9</sup>	50%	32%	32%	30%

\*\*These comparisons are based on extrapolations and/or published results from multiple studies, provided for informational purposes only, and have not been confirmed in head-to-head studies. Treatment outcomes/experiences vary.

\*Zerigo Health's ultraviolet-light-emitting medical device is intended for use in localized phototherapeutic treatment of dermatologic conditions such as psoriasis, vitiligo, atopic dermatitis (eczema), seborrheic dermatitis, and leukoderma on all skin types (I-VI). The device can be used at home or in a physician's office. Individual results may vary. U.S. federal law restricts this device to sale by or on the order of a physician.



## Contact us today to learn how you can grow your practice with Zerigo

1. Begolka WS, Loisele AR, Johnson JK, Guadalupe M, Thibau I. Frequency and Wait Times for Acute Care Needs in Outpatient Care Settings: A Survey – Study of Patients with Atopic Dermatitis. National Eczema Association; Novato, CA. Member self-reported skin clearance, psoriasis, 2018 - 2024
2. Member self-reported skin clearance, psoriasis, 2018-2024
3. Member self-reported satisfaction with Zerigo Skin Health Platform
4. Adherence and Persistence to Biological Drugs for Psoriasis: Systematic Review with Meta-Analysis – PMC <https://pmc.ncbi.nlm.nih.gov/articles/PMC8953925/>
5. https://pmc.ncbi.nlm.nih.gov/articles/PMC8953925/
6. Apremilast Adherence and Persistence in Patients with Psoriasis and Psoriatic Arthritis in the Telehealth Setting Versus the In-person Setting During the COVID-19 Pandemic – PMC 2024;160(12):1320-1328. doi:10.1001/jamadermatol.2024.2877
7. Wu JJ, Feldman SR, Guillemin I, et al. Home- vs Office-Based Narrowband UV-B Phototherapy for Patients With Psoriasis: The LITE Randomized Clinical Trial. JAMA Dermatol. 2024;160(12):1320-1328. doi:10.1001/jamadermatol.2024.2877
8. Study Details | Light Treatment Effectiveness (LITE) Study | ClinicalTrials.gov
9. Full article: Real-world treatment patterns and healthcare costs in patients with psoriasis taking systemic oral or biologic therapies